Pathstone Family Office’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | $5.5M | Buy |
15,820
+8,726
| +123% | +$3.04M | 0.04% | 253 |
|
|
2023
Q2 | $2.55M | Sell |
7,094
-81
| -1% | -$29.1K | 0.04% | 275 |
|
|
2023
Q1 | $2.15M | Sell |
7,175
-19,953
| -74% | -$5.97M | 0.03% | 278 |
|
|
2022
Q4 | $6.93M | Buy |
27,128
+5,438
| +25% | +$1.39M | 0.06% | 223 |
|
|
2022
Q3 | $6.29M | Buy |
21,690
+17,219
| +385% | +$4.99M | 0.06% | 196 |
|
|
2022
Q2 | $1.26M | Buy |
4,471
+506
| +13% | +$143K | 0.03% | 297 |
|
|
2022
Q1 | $1.04M | Sell |
3,965
-518
| -12% | -$135K | 0.02% | 319 |
|
|
2021
Q4 | $985K | Buy |
4,483
+1,861
| +71% | +$409K | 0.02% | 345 |
|
|
2021
Q3 | $475K | Buy |
2,622
+333
| +15% | +$60.3K | 0.01% | 537 |
|
|
2021
Q2 | $462K | Buy |
2,289
+313
| +16% | +$63.2K | 0.01% | 496 |
|
|
2021
Q1 | $425K | Buy |
1,976
+1,375
| +229% | +$296K | 0.01% | 381 |
|
|
2020
Q4 | $142K | Buy |
601
+91
| +18% | +$21.5K | 0.01% | 324 |
|
|
2020
Q3 | $139K | Hold |
510
| – | – | 0.02% | 235 |
|
|
2020
Q2 | $148K | Hold |
510
| – | – | 0.02% | 186 |
|
|
2020
Q1 | $122K | Buy |
510
+261
| +105% | +$62.4K | 0.02% | 207 |
|
|
2019
Q4 | $545K | Hold |
249
| – | – | 0.01% | 281 |
|
|
2019
Q3 | $42K | Hold |
249
| – | – | 0.01% | 297 |
|
|
2019
Q2 | $46K | Hold |
249
| – | – | 0.01% | 339 |
|
|
2019
Q1 | $46K | Buy |
+249
| New | +$46K | 0.01% | 317 |
|
|
2017
Q2 | – | Sell |
-38
| Closed | -$4K | – | 643 |
|
|
2017
Q1 | $4K | Buy |
+38
| New | +$4K | ﹤0.01% | 335 |
|
|
2016
Q4 | – | Sell |
-30
| Closed | -$3K | – | 205 |
|
|
2016
Q3 | $3K | Sell |
30
-27
| -47% | -$2.7K | ﹤0.01% | 181 |
|
|
2016
Q2 | $5K | Hold |
57
| – | – | ﹤0.01% | 181 |
|
|
2016
Q1 | $4K | Buy |
+57
| New | +$4K | 0.01% | 151 |
|